Dirk Schadendorf, MD, on the phase 3 STARBOARD study: first-line encorafenib, binimetinib and pembrolizumab vs. placebo and pembrolizumab in BRAF V600–mutant melanoma. #ESMO26 Watch now: bit.ly/4BtJChb

Guillermo De Velasco, MD, PhD, on enfortumab vedotin + pembrolizumab in refractory advanced melanoma (PLUG-IN GEM 2301) and the CD137/PD-L1 bispecific FS222 in PD-1 inhibitor–resistant melanoma. #ESMO26 Watch now: bit.ly/4zdxUWD

Marcelo Negrao, MD, on updated results for first-line olomorasib + chemo-immunotherapy in KRAS G12C–mutant NSCLC from LOXO-RAS-20001 and SUNRAY-01. #ESMO26 Watch now: bit.ly/47D1IzN

David Gandara, MD, on the randomized ASTRIDE trial: serplulimab or atezolizumab + chemotherapy in US patients with extensive-stage small cell lung cancer. #ESMO26 Watch now: bit.ly/47FUfQw

Federico Cappuzzo, MD, on a phase 2 trial of OSE2101 plus docetaxel or nivolumab as second-line therapy in metastatic NSCLC after first-line chemo-immunotherapy. #ESMO26 Watch now: bit.ly/47D1tVp

Tamim Niazi, MD (@niazi_Dr7), on the interim analysis of the phase 3 DASL-HiCaP trial: darolutamide + ADT with definitive or salvage radiation therapy for localised, very high-risk prostate cancer. #ESMO26 Watch now: bit.ly/48gMnoE

Benjamin Garmezy, MD, on JNJ-6143, a first-in-class oral AR-targeted RIPTAC™, at the optimal dose in metastatic prostate cancer, including high-risk molecular features. #ESMO26 Watch now: bit.ly/4dYJ1dp

Sara Lonardi, MD, on final overall survival from CheckMate 8HW: nivolumab + ipilimumab vs. nivolumab or chemotherapy in MSI-H/dMMR metastatic colorectal cancer. #ESMO26 Watch now: bit.ly/4zd51ty

Andrea Cercek, MD, on first results from the global registrational AZUR-1 trial: clinical complete response with dostarlimab alone in dMMR/MSI-H locally advanced rectal cancer. #ESMO26 Watch now: bit.ly/4eOJDCv

Sanjiv Gangaram-Panday, PhD, on long-term results from the SANO trial: active surveillance vs. standard surgery after neoadjuvant chemoradiotherapy for esophageal cancer. #ESMO26 Watch now: bit.ly/4z9IkWW

Hong Jae Chon, MD, PhD, on first phase 1 dose-escalation and dose-optimization data for BGB-B2033, a GPC3 × 4-1BB bispecific antibody, in advanced hepatocellular carcinoma. #ESMO26 Watch now: bit.ly/4yKmqc1

Carlos Barcenas, MD, MSc, on pre-interim results from B-STRONGER-I: ultrasensitive ctDNA monitoring during neoadjuvant treatment in early-stage triple-negative breast cancer. #ESMO26 Watch now: bit.ly/4Bk5ag6

Hongxia Wang, PhD, on safety and efficacy of SYS6043, a novel B7-H3–targeting antibody-drug conjugate, in advanced breast cancer. #ESMO26 Watch now: bit.ly/4ss9XIj

Kamran Ahmed, MD, on the phase 2 INSPIRE-LM study: radiation therapy followed by intrathecal trastuzumab/pertuzumab for HER2+ breast cancer leptomeningeal metastasis. #ESMO26 Watch now: bit.ly/3UjVOAs

Mehmet Ali Nahit Sendur, MD, on calderasib (MK-1084), alone or in combination, in KRAS G12C–mutant metastatic NSCLC. #ESMO26 Watch now: bit.ly/4zVTPBB

Byoung Chul Cho, MD, PhD (@cbcbc1971), on first data from the phase 2 ROSETTA Lung-107 trial of pumitamig (PD-L1 × VEGF-A bispecific) + docetaxel after chemoimmunotherapy in NSCLC. #ESMO26 Watch now: bit.ly/4dWpn1z

Chantal Decroisette, MD, on the phase 3 PERSEE trial: first-line pembrolizumab with or without platinum-based chemotherapy in advanced NSCLC with PD-L1 ≥50%. #ESMO26 Watch now: bit.ly/4ig8bFH

Daniel Khalaf, MD, on patient-reported quality of life with docetaxel vs. lutetium-177-PSMA-617 in mCRPC from the CCTG PR21 trial. #ESMO26 Watch now: bit.ly/4zRF5n2

Chantal Decroisette, MD, on the phase 3 PERSEE trial: first-line pembrolizumab with or without platinum-based chemotherapy in advanced NSCLC with PD-L1 ≥50%. #ESMO26 Watch now: bit.ly/4ig8bFH

Sarah Howlett, MD, on using a transcriptome classifier to stratify risk and guide ARPI intensification in clinically very high-risk prostate cancer. #ESMO26 Watch now: bit.ly/4igzrUy